Onur Cagri Kutlu

Closest collaborators

The 14 strongest of 14 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

1. Claudius H. Conrad · 5 shared papers, 2020–2023 · strength 0.79
   • Paper ASO AUTHOR REFLECTIONS: Laparoscopic Distal Pancreatectomy for Pancreatic Cancer: Good, Bad, or Even Ugly? DOI 10.1245/s10434-021-10332-3↗
   • Paper R1 pancreatic cancer patients benefit from chemoradiation when initiation of adjuvant therapy is delayed. DOI 10.1016/j.suronc.2023.101961↗
   • Paper Trends in Preoperative Chemotherapy Utilization for Proximal Pancreatic Cancer: Are We Making Progress? DOI 10.1007/s11605-022-05336-7↗
2. Eduardo A. Vega · 5 shared papers, 2020–2023 · strength 0.79
   • Paper ASO AUTHOR REFLECTIONS: Laparoscopic Distal Pancreatectomy for Pancreatic Cancer: Good, Bad, or Even Ugly? DOI 10.1245/s10434-021-10332-3↗
   • Paper R1 pancreatic cancer patients benefit from chemoradiation when initiation of adjuvant therapy is delayed. DOI 10.1016/j.suronc.2023.101961↗
   • Paper Trends in Preoperative Chemotherapy Utilization for Proximal Pancreatic Cancer: Are We Making Progress? DOI 10.1007/s11605-022-05336-7↗
3. Omid Salehi · 4 shared papers, 2020–2022 · strength 0.61
   • Paper ASO AUTHOR REFLECTIONS: Laparoscopic Distal Pancreatectomy for Pancreatic Cancer: Good, Bad, or Even Ugly? DOI 10.1245/s10434-021-10332-3↗
   • Paper Trends in Preoperative Chemotherapy Utilization for Proximal Pancreatic Cancer: Are We Making Progress? DOI 10.1007/s11605-022-05336-7↗
   • Paper The impact of chemotherapy sequencing on resectable pancreatic cancer by stage. DOI 10.1016/j.suronc.2021.101694↗
4. Ahmed Alnajar · 1 shared paper, 2026 · strength 0.36
   • Paper Assessing Textbook Oncologic Outcomes in Distal Pancreatectomy for Pancreatic Adenocarcinoma: A National Cancer Databas… DOI 10.3390/jcm15103967↗
5. Danny Sleeman · 1 shared paper, 2026 · strength 0.36
   • Paper Assessing Textbook Oncologic Outcomes in Distal Pancreatectomy for Pancreatic Adenocarcinoma: A National Cancer Databas… DOI 10.3390/jcm15103967↗
6. Sebastián Mellado · 2 shared papers, 2022–2023 · strength 0.33
   • Paper R1 pancreatic cancer patients benefit from chemoradiation when initiation of adjuvant therapy is delayed. DOI 10.1016/j.suronc.2023.101961↗
   • Paper Trends in Preoperative Chemotherapy Utilization for Proximal Pancreatic Cancer: Are We Making Progress? DOI 10.1007/s11605-022-05336-7↗
7. Ariana M. Chirban · 1 shared paper, 2023 · strength 0.18
   • Paper R1 pancreatic cancer patients benefit from chemoradiation when initiation of adjuvant therapy is delayed. DOI 10.1016/j.suronc.2023.101961↗
8. Oscar Salirrosas · 1 shared paper, 2023 · strength 0.18
   • Paper R1 pancreatic cancer patients benefit from chemoradiation when initiation of adjuvant therapy is delayed. DOI 10.1016/j.suronc.2023.101961↗
9. Ernest Ramsay Camp · 1 shared paper, 2022 · strength 0.16
   • Paper Factors associated with inability to return to intended oncologic treatment in pancreatic cancer. DOI 10.1016/j.amjsurg.2022.02.058↗
10. William E. Fisher · 1 shared paper, 2022 · strength 0.16
    • Paper Factors associated with inability to return to intended oncologic treatment in pancreatic cancer. DOI 10.1016/j.amjsurg.2022.02.058↗
11. Eric Jay Silberfein · 1 shared paper, 2022 · strength 0.16
    • Paper Factors associated with inability to return to intended oncologic treatment in pancreatic cancer. DOI 10.1016/j.amjsurg.2022.02.058↗
12. Townes A Mickel · 1 shared paper, 2022 · strength 0.16
    • Paper Factors associated with inability to return to intended oncologic treatment in pancreatic cancer. DOI 10.1016/j.amjsurg.2022.02.058↗
13. George Van Buren · 1 shared paper, 2022 · strength 0.16
    • Paper Factors associated with inability to return to intended oncologic treatment in pancreatic cancer. DOI 10.1016/j.amjsurg.2022.02.058↗
14. David J. Lee · 1 shared paper, 2022 · strength 0.15
    • Paper The impact of chemotherapy sequencing on resectable pancreatic cancer by stage. DOI 10.1016/j.suronc.2021.101694↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.